CoChat

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Open access

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Abstract

Background PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant.Methods This first-in-human, randomised, double-blind, placebo-controlled, dose escalation trial was done in two staggered phases, a phase 1A trial in 18-35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso. Volunteers were recruited into four sequential cohorts receiving PRIMVAC intramuscularly at day 0, 28, and 56: two cohorts in France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC. Volunteers were randomly assigned (1:1) to two groups (PRIMVAC adjuvanted with either Alhydrogel or GLA-SE) in France and randomly assigned (2:2:1) to three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo) in Burkina Faso. Randomisation was centralised, using stratification by cohort and blocks of variable size, and syringes were masked by opaque labels. The primary endpoint was the proportion of participants with any grade 3 or higher adverse reaction to vaccination up until day 35. Safety at later time points as well as humoral and cellular immunogenicity were assessed in secondary endpoints. This trial is registered with ClinicalTrials.gov, NCT02658253.Findings Between April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included. No serious adverse event related to the vaccine occurred. PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57). PRIMVAC antibody titres reached a peak (geometric mean 11 843·0, optical density [OD] 1·0, 95% CI 7559·8-18 552·9 with 100 μg dose and GLA-SE) 1 week after the third vaccination (day 63). Compared with Alhydrogel, GLA-SE tended to improve the PRIMVAC antibody response (geometric mean 2163·5, OD 1·0, 95% CI 1315·7-3557·7 with 100 μg dose and Alhydrogel at day 63). 1 year after the last vaccination, 20 (71%) of 28 women who were vaccinated with PRIMVAC/Alhydrogel and 26 (93%) of 28 women who were vaccinated with PRIMVAC/GLA-SE still had anti-PRIMVAC antibodies, although antibody magnitude was markedly lower (452·4, OD 1·0, 95% CI 321·8-636·1 with 100 μg dose and GLA-SE). These antibodies reacted with native homologous VAR2CSA expressed by NF54-CSA infected erythrocytes (fold change from baseline at day 63 with 100 μg dose and GLA-SE: 10·74, 95% CI 8·36-13·79). Limited cross-recognition, restricted to sera collected from women that received the 100 μg PRIMVAC dose, was observed against heterologous VAR2CSA variants expressed by FCR3-CSA (fold change from baseline at day 63: 1·49, 95% CI 1·19-1·88) and 7G8-CSA infected erythrocytes (1·2, 1·08-1·34).Interpretation PRIMVAC adjuvanted with Alhydrogel or GLA-SE had an acceptable safety profile, was immunogenic, and induced functional antibodies reacting with the homologous VAR2CSA variant expressed by NF54-CSA infected erythrocytes. Cross-reactivity against heterologous VAR2CSA variants was limited and only observed in the higher dose group. An alternate schedule of immunisation, antigen dose, and combinations with other VAR2CSA-based vaccines are envisaged to improve the cross-reactivity against heterologous VAR2CSA variants.Funding Bundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(19)30739-x

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 124

Metadata

Authors
Sirima, S. B., Richert, L., Chêne, A., Konate, A. T., Campion, C., Dechavanne, S., Semblat, J.-P., Benhamouda, N., Bahuaud, M., Loulergue, P., Ouédraogo, A., Nébié, I., Kabore, M., Kargougou, D., Barry, A., Ouattara, S. M., Boilet, V., Allais, F., Roguet, G., Havelange, N., Lopez-Perez, E., Kuppers, A., Konaté, E., Roussillon, C., Kanté, M., Belarbi, L., Diarra, A., Henry, N., Soulama, I., Ouédraogo, A., Esperou, H., Leroy, O., Batteux, F., Tartour, E., Viebig, N. K., Thiebaut, R., Launay, O., & Gamain, B.
Affiliations
  • Centre National de Recherche et de Formation sur le Paludisme (BF)
  • Institut national de recherche en sciences et technologies du numérique (FR)
  • Inserm (FR)
  • Université de Bordeaux (FR)
  • Hôpital Cochin (FR)
  • University Hospital Heidelberg (DE)
Corresponding author
Gamain, Benoît
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2020-05
Volume
20
Issue
5
Pages
585-597
ISSN
1473-3099 (ISSN-L)
OpenAlex
W3004500121
Cited by
124
References
33
Citations by year
2026: 11 · 2025: 13 · 2024: 20 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 9
FWCI
14.98
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Infectious Diseases (acceptedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • HAL Portal Artxiker (Hindustan Aeronautics Limited (India)) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
Funders
  • Irish Aid
  • Institut National de la Transfusion Sanguine
  • Department of Foreign Affairs and Trade, Ireland
  • Agence Nationale de la Recherche
  • Bundesministerium für Bildung und Forschung
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
VAR2CSA, placental malaria, Plasmodium falciparum, malaria vaccine, Alhydrogel, GLA-SE, vaccine adjuvants, vaccine safety, immunogenicity, antibody titers, T cell response, dose escalation, pregnant women, malaria in pregnancy, seroconversion, non-pregnant women, first-in-human
MeSH terms
Immunogenicity, Vaccine, Adjuvants, Immunologic, Adolescent, Adult, Aluminum Hydroxide, Antibody Formation, Burkina Faso, Double-Blind Method, Female, France, Glucosides, Humans, Immunization, Lipid A, Plasmodium falciparum, Vaccination, Malaria, Falciparum, Malaria Vaccines, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1016/s1473-3099(19)30739-x
The paper
Sirima, S. B., Richert, L., Chêne, A., Konate, A. T., Campion, C., Dechavanne, S., Semblat, J.-P., Benhamouda, N., Bahuaud, M., Loulergue, P., Ouédraogo, A., Nébié, I., Kabore, M., Kargougou, D., Barry, A., Ouattara, S. M., Boilet, V., Allais, F., Roguet, G., . . . Gamain, B. (2020). PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(19)30739-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.